Mucositis News and Research

RSS
AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Periogenix to be introduced at International Symposium for Periodontics & Restorative Dentistry

Periogenix to be introduced at International Symposium for Periodontics & Restorative Dentistry

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Scientists combine two agents to treat patients with multiple myeloma

Scientists combine two agents to treat patients with multiple myeloma

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

New research identifies cellular channel that regulates skin and hair growth

New research identifies cellular channel that regulates skin and hair growth

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

JCOM receives approval from KFDA to commercialize MuGard in Korea

JCOM receives approval from KFDA to commercialize MuGard in Korea

New online resource to help people with Oral Mucositis launched

New online resource to help people with Oral Mucositis launched

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

University of Maryland School of Nursing to spearhead new Center for Pain Studies

University of Maryland School of Nursing to spearhead new Center for Pain Studies

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Update on European commercial launch of MuGard for oral mucositis provided

Update on European commercial launch of MuGard for oral mucositis provided